Trial reportThe New England journal of medicine2026
Sacituzumab Tirumotecan in EGFR-TKI-Resistant,
Trial report in The New England journal of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Evolution and recent advances in antibody-drug conjugate therapy for lung cancer: a comprehensive systematic review based on the Trialtrove database (inception to July 1, 2025).Frontiers in oncology · 2026Pooled it
- Treatment prioritization of chemotherapy-anchored regimens after EGFR-TKI failure in EGFR-mutant NSCLC: a systematic review, pairwise meta-analysis and Bayesian network meta-analysis with probabilistic multi-criteria decision analysis.Frontiers in immunology · 2026Pooled it
- Efficacy and safety of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor resistance: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a detailed safety analysis of the randomized OptiTROP-Breast01 study.Breast cancer research : BCR · 2026Trial
- Three-year adjuvant treatment of icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma (ICWIP): a randomized, double-blind, placebo-controlled phase 3 trial.Signal transduction and targeted therapy · 2026Trial
- EGFR-antibody-decorated cancer-cell-membrane-coated MOF nanoplatform enables targeted delivery of the STING agonist diABZI for pancreatic cancer immunotherapy.International journal of pharmaceutics: X · 2026Article
- TROP2 expression in gastric and GEJ adenocarcinomas: associations with clinicopathological features, biomarkers, and treatment outcomes.ESMO gastrointestinal oncology · 2026Article
- Clinical and genomic determinants of early treatment discontinuation in non-small-cell lung cancer: an analysis of the AACR Project GENIE Biopharma Collaborative NSCLC dataset.ESMO real world data and digital oncology · 2026Article
- Cancer metastasis: biological mechanisms, therapeutic bottlenecks, and emerging interventions.Journal of hematology & oncology · 2026Review
- Antibody-drug conjugates in lung cancer: clinical development, therapeutic advances, and emerging challenges.Cancer chemotherapy and pharmacology · 2026Review
- Efficacy and safety of third-generationTranslational lung cancer research · 2026Article
- EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the "Rebiopsy on Osi" study).The oncologist · 2026Article
- Pragmatic Management of EGFR-Mutant NSCLC After Progression on Osimertinib: Canadian Expert Perspectives.Current oncology (Toronto, Ont.) · 2026Review
- Antibody-Drug Conjugates and Peptide-Drug Conjugates: Current Understandings and Future Perspectives.MedComm · 2026Review
- Detection of Metastatic Lesions in Esophageal Cancer Using a TROP2 Antibody-Based Near-Infrared Probe.Advanced healthcare materials · 2026Article
- Trophoblast cell-surface antigen 2-targeted "sacituzumab tirumotecan": a new approach for epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small cell lung cancer.Translational lung cancer research · 2026Article
- Prevalence and Clinical Implications of Somatic and Germline EGFR Mutations in Patients with Non-Small-Cell Lung Cancer.Cancers · 2026Review
- Targeting ClassicalCancers · 2026Review
- Anti-TROP2 Antibody Drug Conjugates in EGFR-Mutant Non-Small Cell Lung Cancer: Biological Rationale and Clinical Challenges.Pharmaceutics · 2026Review
- New Treatment Strategies for Rare Genomic Alterations:Cancers · 2026Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
34 authors.
Funding
Abstract
backgroundSacituzumab tirumotecan (sac-TMT) is an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 that has shown significant survival benefits in patients with
methodsIn this phase 3 trial, we enrolled patients with
resultsOverall, 376 patients underwent randomization, with 188 assigned to each group. After a median follow-up of 18.9 months, the median progression-free survival was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group (hazard ratio for disease progression or death, 0.49; 95% confidence interval [CI], 0.39 to 0.62). Overall survival was significantly longer with sac-TMT than with chemotherapy (hazard ratio for death, 0.60; 95% CI, 0.44 to 0.82; two-sided P = 0.001); 18-month overall survival was 65.8% and 48.0%, respectively. Treatment-related adverse events of grade 3 or higher occurred in 58.0% of patients receiving sac-TMT and in 53.8% of those receiving chemotherapy, with the most common being a decreased neutrophil count (39.9% vs. 33.0%); treatment-related serious adverse events occurred in 9.0% and 17.6%, respectively.
conclusionsIn patients with
Indexed as
Identifiers
41124220What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.